Literature DB >> 31907995

Demyelinating polyneuropathy in goats lacking prion protein.

Fredrik S Skedsmo1, Giulia Malachin2, Dag Inge Våge3, Mie Marie Hammervold3, Øyvind Salvesen4, Cecilie Ersdal4, Birgit Ranheim4, Marit H Stafsnes5, Zdenka Bartosova5, Per Bruheim5, Karin H Jäderlund1, Kaspar Matiasek6, Arild Espenes2, Michael A Tranulis2.   

Abstract

Studies in mice with ablation of Prnp, the gene that encodes the cellular prion protein (PrPC ), have led to the hypothesis that PrPC is important for peripheral nerve myelin maintenance. Here, we have used a nontransgenic animal model to put this idea to the test; namely, goats that, due to a naturally occurring nonsense mutation, lack PrPC . Teased nerve fiber preparation revealed a demyelinating pathology in goats without PrPC . Affected nerves were invaded by macrophages and T cells and displayed vacuolated fibers, shrunken axons, and onion bulbs. Peripheral nerve lipid composition was similar in young goats with or without PrPC , but markedly different between corresponding groups of adult goats, reflecting the progressive nature of the neuropathy. This is the first report of a subclinical demyelinating polyneuropathy caused by loss of PrPC function in a nontransgenic mammal.
© 2019 Norwegian University of Life Sciences. The FASEB Journal published by John Wiley & Sons Ltd on behalf of The FASEB Journal.

Entities:  

Keywords:  PRNP haplotype; lipidomic; myelin; neuropathy

Mesh:

Substances:

Year:  2019        PMID: 31907995     DOI: 10.1096/fj.201902588R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  14 in total

1.  High Throughput Semiquantitative UHPSFC-MS/MS Lipid Profiling and Lipid Class Determination.

Authors:  Zdenka Bartosova; Susana Villa Gonzalez; André Voigt; Per Bruheim
Journal:  J Chromatogr Sci       Date:  2021-06-21       Impact factor: 1.618

Review 2.  The multiple functions of PrPC in physiological, cancer, and neurodegenerative contexts.

Authors:  Izabella Grimaldi; Felipe Saceanu Leser; José Marcos Janeiro; Bárbara Gomes da Rosa; Ana Clara Campanelli; Luciana Romão; Flavia Regina Souza Lima
Journal:  J Mol Med (Berl)       Date:  2022-09-03       Impact factor: 5.606

3.  Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study.

Authors:  Emma Jones; Holger Hummerich; Emmanuelle Viré; James Uphill; Athanasios Dimitriadis; Helen Speedy; Tracy Campbell; Penny Norsworthy; Liam Quinn; Jerome Whitfield; Jacqueline Linehan; Zane Jaunmuktane; Sebastian Brandner; Parmjit Jat; Akin Nihat; Tze How Mok; Parvin Ahmed; Steven Collins; Christiane Stehmann; Shannon Sarros; Gabor G Kovacs; Michael D Geschwind; Aili Golubjatnikov; Karl Frontzek; Herbert Budka; Adriano Aguzzi; Hata Karamujić-Čomić; Sven J van der Lee; Carla A Ibrahim-Verbaas; Cornelia M van Duijn; Beata Sikorska; Ewa Golanska; Pawel P Liberski; Miguel Calero; Olga Calero; Pascual Sanchez-Juan; Antonio Salas; Federico Martinón-Torres; Elodie Bouaziz-Amar; Stéphane Haïk; Jean-Louis Laplanche; Jean-Phillipe Brandel; Phillipe Amouyel; Jean-Charles Lambert; Piero Parchi; Anna Bartoletti-Stella; Sabina Capellari; Anna Poleggi; Anna Ladogana; Maurizio Pocchiari; Serena Aneli; Giuseppe Matullo; Richard Knight; Saima Zafar; Inga Zerr; Stephanie Booth; Michael B Coulthart; Gerard H Jansen; Katie Glisic; Janis Blevins; Pierluigi Gambetti; Jiri Safar; Brian Appleby; John Collinge; Simon Mead
Journal:  Lancet Neurol       Date:  2020-09-16       Impact factor: 44.182

4.  Prion protein in myelin maintenance: what does the goat say?

Authors:  Fredrik S Skedsmo; Arild Espenes; Michael A Tranulis
Journal:  Neural Regen Res       Date:  2021-06       Impact factor: 5.135

Review 5.  Neuroprotective effect and potential of cellular prion protein and its cleavage products for treatment of neurodegenerative disorders part I. a literature review.

Authors:  Emily Dexter; Qingzhong Kong
Journal:  Expert Rev Neurother       Date:  2021-09-02       Impact factor: 4.287

6.  Soluble dimeric prion protein ligand activates Adgrg6 receptor but does not rescue early signs of demyelination in PrP-deficient mice.

Authors:  Anna Henzi; Assunta Senatore; Asvin K K Lakkaraju; Claudia Scheckel; Jonas Mühle; Regina Reimann; Silvia Sorce; Gebhard Schertler; Klaus V Toyka; Adriano Aguzzi
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

Review 7.  Small Ruminants and Its Use in Regenerative Medicine: Recent Works and Future Perspectives.

Authors:  Rui Damásio Alvites; Mariana Vieira Branquinho; Ana Catarina Sousa; Bruna Lopes; Patrícia Sousa; Carla Mendonça; Luís Miguel Atayde; Ana Colette Maurício
Journal:  Biology (Basel)       Date:  2021-03-22

8.  Experimental determination of Escherichia coli biomass composition for constraint-based metabolic modeling.

Authors:  Vetle Simensen; Christian Schulz; Emil Karlsen; Signe Bråtelund; Idun Burgos; Lilja Brekke Thorfinnsdottir; Laura García-Calvo; Per Bruheim; Eivind Almaas
Journal:  PLoS One       Date:  2022-01-27       Impact factor: 3.240

9.  Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints.

Authors:  Eric Vallabh Minikel; Hien T Zhao; Jason Le; Jill O'Moore; Rose Pitstick; Samantha Graffam; George A Carlson; Michael P Kavanaugh; Jasna Kriz; Jae Beom Kim; Jiyan Ma; Holger Wille; Judd Aiken; Deborah McKenzie; Katsumi Doh-Ura; Matthew Beck; Rhonda O'Keefe; Jacquelyn Stathopoulos; Tyler Caron; Stuart L Schreiber; Jeffrey B Carroll; Holly B Kordasiewicz; Deborah E Cabin; Sonia M Vallabh
Journal:  Nucleic Acids Res       Date:  2020-11-04       Impact factor: 16.971

Review 10.  Classical and Atypical Scrapie in Sheep and Goats. Review on the Etiology, Genetic Factors, Pathogenesis, Diagnosis, and Control Measures of Both Diseases.

Authors:  Cristina Acín; Rosa Bolea; Marta Monzón; Eva Monleón; Bernardino Moreno; Hicham Filali; Belén Marín; Diego Sola; Marina Betancor; Isabel M Guijarro; Mirta García; Antonia Vargas; Juan José Badiola
Journal:  Animals (Basel)       Date:  2021-03-04       Impact factor: 2.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.